相关实验视频

Updated: Jan 10, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

在急性髓性白血病中BRAF突变的预后和治疗影响

Darren Lee¹, Yazan Abu-Shihab², Kate Plas³

¹University of Cincinnati College of Medicine, Cincinnati OH.

bioRxiv : the preprint server for biology

|November 24, 2025

概括

虽然在急性髓性白血病 (AML) 中很少见,但BRAF突变与糟糕的结果有关. 这项研究揭示了BRAF突变AML的独特分子模式和糟糕的生存率,这表明了新的治疗点.

科学领域:

血液学血液学血液学
在瘤学瘤学.
分子生物学分子生物学

背景情况:

在急性髓性白血病 (AML) 中,RAS/MAPK路径突变很常见.
在AML中,BRAF突变并不常见,但与不良结果有关.
缺乏对BRAF突变的AML临床和分子特征的全面分析.

研究的目的:

描述BRAF突变的AML的临床和分子格局.
通过单细胞多组学来研究突变模式,共同突变和免疫表型.
为了确定BRAF突变的AML.潜在的治疗策略.

主要方法:

分析了5779个临床和分子注释的AML患者样本.
识别正规和非正规的BRAF突变.
一组AML样本的单细胞多原子分析.

主要成果:

在大约1%的AML患者中发现了BRAF突变,这些突变富含了与骨髓质疏松症相关的AML (AML-MR).
大多数BRAF突变发生在V600热点之外.
单细胞分析揭示了BRAF突变类特定的共同突变和免疫类型的模式,BRAF和其他信号突变同时发生在同一个细胞内.
即使使用基于venetoclax的治疗方案,BRAF突变AML患者的整体存活率也很差.

结论:

BRAF突变代表了AML的一个独特的分子子集,预后不佳.
单细胞多组学提供了关于BRAF突变异质性和共突变格局的见解.
向疗法可能为BRAF突变的AML提供新的治疗途径.

更多相关视频

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Published on: March 1, 2024

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

MAPK Signaling Cascades

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

The Ras Gene

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...